Medicare Initiates GLP-1 Bridge Program for Weight Management
The Department of Health and Human Services has launched a pilot initiative under the Medicare GLP-1 Bridge program, starting July 1, 2023. This program is designed to lower out-of-pocket costs for selected weight loss medications, allowing eligible Medicare Part D enrollees to obtain specific GLP-1 drugs for $50 per month. The initiative will run through December 31, 2027, marking a significant shift in Medicare's policy, which has historically excluded coverage for weight loss drugs.
This pilot program has the potential to impact approximately 14 million Americans. Currently, Medicare covers GLP-1 drugs for conditions such as type 2 diabetes and obstructive sleep apnea, but these beneficiaries are not eligible for the new program's additional coverage. Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, emphasized the importance of removing financial barriers to make advanced medical treatments more accessible and affordable for seniors.
Program Specifics and Participant Eligibility
The initiative includes several GLP-1 medications, excluding Zepbound single-use pens and vials. Participants must be at least 18 years old and using the medication primarily for weight management. Notably, the $50 monthly copayment does not apply towards the annual Part D deductible or out-of-pocket maximums for 2026, which is a significant consideration for beneficiaries.
While the program significantly reduces consumer costs—from a self-pay range of $149-$1,349 per month—industry experts express concerns regarding its temporary nature and operational constraints. Dr. Kanwar Kelley, CEO of Side Health, appreciates the increased accessibility yet highlights potential disruptions in continuity once the program ends. Similarly, Dr. Mir Ali of MemorialCare Surgical Weight Loss Center welcomes the cost reduction but questions its long-term impact.
Industry Perspectives and Future Considerations
Meredith Freed from the Kaiser Family Foundation emphasized that although the program improves access, its limited duration may interfere with ongoing care provision. Additionally, Stanford University's Dr. Kevin Schulman sees the program as an insightful experiment in managing overall healthcare costs. Despite these findings, concerns remain about the exclusion of individuals already receiving GLP-1 medications for other health conditions.
GLP-1 medications, effective for weight and type 2 diabetes management, work by suppressing appetite and regulating blood sugar levels. They are available in various delivery forms, including weekly injections and daily oral tablets. Aside from weight management, these medications can potentially benefit heart and cognitive health; however, they require lifestyle modifications to maintain long-term efficacy.